Home > Dermatology > AAD 2019 > Vitiligo: The Beginning of a New Era > JAK-inhibitors: an emerging treatment option for vitiligo

JAK-inhibitors: an emerging treatment option for vitiligo

Presented By
Prof. John Harris, University of Massachusetts, USA
Conference
AAD 2019

Therapeutic options have historically been limited. JAK inhibitors are a novel therapeutic possibility, which have shown to be remarkably effective and are currently being tested in clinical trials.

Research in vitiligo has made significant progress in the past 10 years. “Our improved understanding of its pathogenesis is leading to encouraging new treatments,” said Prof. John Harris (University of Massachusetts, USA) [1]. The most promising strategies at this time focus on targeted immunotherapy.

Vitiligo is an autoimmune disease of the skin mediated by CD8+ T cells that kill melanocytes. In addition, expression of IFN-γ is increased in the lesional skin. Neutralisation of IFN-γ prevents CD8(+) T cell accumulation and, as a result, depigmentation, suggesting a therapeutic potential for this approach [2]. In addition, the chemokine CXCL10 plays a critical role in both the progression and maintenance of vitiligo [3]. JAK inhibitors are effective in vi...



Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on